Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287308 | 0.84 | MMP8 (0.56) | MEN1KMT2AMMP8SMN1; SMN2TSHR | |
| SCHEMBL30062331 | 0.84 | MMP8 (0.56) | MEN1KMT2AMMP8SMN1; SMN2TSHR | |
| SCHEMBL10546414 | 0.83 | CASP1 (0.55) | MEN1KMT2AMMP8ALDH1A1MAPT | |
| SCHEMBL9750600 | 0.83 | MAPT (0.47) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL7636543 | 0.81 | MEN1 (0.54) | MEN1KMT2AMMP8ALDH1A1MAPT | |
| SCHEMBL496468 | 0.80 | KMT2A (0.50) | KMT2ATSHRLMNACYP1A2CYP2D6 | |
| SCHEMBL5962065 | 0.80 | MEN1 (0.43) | MEN1KMT2AMMP8ALDH1A1MAPT | |
| SCHEMBL5964020 | 0.79 | CES2 (0.60) | MEN1KMT2AMMP8ALDH1A1MAPT | |
| SCHEMBL6558799 | 0.79 | MMP8 (0.64) | MEN1KMT2AMMP8ALDH1A1MAPT | |
| SCHEMBL10964474 | 0.79 | MEN1 (0.49) | MEN1KMT2AMMP8ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605784-B | Aza-bridged-ring compound | ASTELLAS PHARMA INC JP | 2013-04-10 | — | — | CN | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| CN-101605784-A | Aza-bridged-ring compound | ASTELLAS PHARMA INC (JP) | 2009-12-16 | — | — | CN | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-5378803-A | Analgesics, substance P antagonists, peptides containing thiazole, oxazole or imidazole ring and indole ring | STERLING WINTHROP INC. (US) | 1995-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | MEN1 4138/4885KMT2A 496/4885MMP8 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.